NYSE:NVO Novo Nordisk A/S Q2 2026 Earnings Results & Report $38.60 -0.04 (-0.10%) Closing price 10/12/2026 03:59 PM EasternExtended Trading$38.51 -0.09 (-0.24%) As of 10/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Novo Nordisk A/S reported Q2 2026 earnings on June 30, 2026. The company reported EPS of $0.9440, while revenue was $11.98 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJune 30, 2026TimeAfter Market Closes Novo Nordisk A/S EPS ResultsActual EPS$0.9440Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersNovo Nordisk A/S Revenue ResultsActual Revenue$11.98 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNovo Nordisk A/S' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile Novo Nordisk A/S Q2 2026 Earnings FAQ Did Novo Nordisk A/S beat earnings estimates for Q2 2026? Novo Nordisk A/S (NYSE:NVO) reported earnings of $0.9440 per share for Q2 2026. The report was announced on Tuesday, June 30, 2026. What was Novo Nordisk A/S' revenue for Q2 2026? Novo Nordisk A/S reported revenue of $11.98 billion for Q2 2026. When is Novo Nordisk A/S' next earnings date? Novo Nordisk A/S' next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novo Nordisk A/S on the company's earnings history page. Novo Nordisk A/S Earnings HeadlinesNovo Nordisk A/S - share repurchase programmeOctober 12 at 8:35 AM | finance.yahoo.comNovo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data LandOctober 9, 2026 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average GrowthOctober 9, 2026 | finance.yahoo.comUBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.October 8, 2026 | fool.comNovo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’October 8, 2026 | barchart.comSee More Novo Nordisk A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novo Nordisk A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novo Nordisk A/S and other key companies, straight to your email. Email Address About Novo Nordisk A/SNovo Nordisk A/S (NYSE:NVO) is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy. The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments. Novo Nordisk conducts research in areas such as cardiometabolic disease and related chronic conditions, and serves patients and healthcare providers across markets worldwide. Novo Nordisk traces its origins to two Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, founded in the 1920s. The businesses merged in 1989 to form Novo Nordisk. The company is headquartered in Bagsværd, Denmark, and its shares trade on Nasdaq Copenhagen, while its American depositary receipts trade on the New York Stock Exchange under the symbol NVO.View Novo Nordisk A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
